Building on their existing collaboration, the companies have signed a new agreement to focus on lead optimization of drug candidates identified by Variational AI’s Enki™ generative AI platform and ...
Amazon S3 on MSN
The surprising physics behind smarter artificial intelligence
What if AI had its own periodic table? Scientists at Emory University have just unveiled a groundbreaking mathematical ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...
Vancouver firm's AI platform will generate chemical compounds based on Merck’s therapeutic targets. A Vancouver startup using artificial intelligence (AI) to discover new drugs has struck a deal with ...
Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback